Doximity (NYSE:DOCS) Given New $26.00 Price Target at Mizuho

Doximity (NYSE:DOCS) had its target price dropped by Mizuho from $34.00 to $26.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s target price points to a potential upside of 10.57% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. KeyCorp cut shares of Doximity from an “overweight” rating to a “sector weight” rating in a research report on Thursday. Loop Capital set a $31.00 price objective on shares of Doximity in a research report on Tuesday, March 17th. Jefferies Financial Group cut shares of Doximity from a “buy” rating to a “hold” rating and set a $19.00 price objective for the company. in a research report on Thursday. Robert W. Baird reaffirmed a “neutral” rating and set a $18.00 price objective (down from $40.00) on shares of Doximity in a research report on Thursday. Finally, Truist Financial reaffirmed a “hold” rating and set a $29.00 price objective (down from $37.00) on shares of Doximity in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.20.

Doximity Price Performance

Shares of DOCS stock opened at $23.52 on Thursday. Doximity has a 52 week low of $20.55 and a 52 week high of $76.51. The stock has a market cap of $4.34 billion, a PE ratio of 19.60, a PEG ratio of 1.88 and a beta of 1.36. The firm has a 50 day simple moving average of $24.27.

Doximity announced that its Board of Directors has approved a stock buyback program on Thursday, February 5th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 8% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Doximity

In related news, Director Kira Scherer Wampler sold 9,000 shares of Doximity stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total transaction of $234,540.00. Following the sale, the director directly owned 19,839 shares in the company, valued at $517,004.34. This trade represents a 31.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of Doximity stock in a transaction on Monday, May 11th. The stock was sold at an average price of $25.77, for a total transaction of $59,502.93. Following the sale, the insider owned 89,396 shares in the company, valued at $2,303,734.92. This represents a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,055 shares of company stock worth $456,061 over the last quarter. 31.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Doximity

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after purchasing an additional 518,916 shares during the period. William Blair Investment Management LLC increased its stake in Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after purchasing an additional 609,775 shares during the period. Capital World Investors increased its stake in Doximity by 5.1% in the fourth quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock valued at $250,398,000 after purchasing an additional 273,444 shares during the period. Franklin Resources Inc. increased its stake in Doximity by 6.2% in the third quarter. Franklin Resources Inc. now owns 3,357,505 shares of the company’s stock valued at $245,601,000 after purchasing an additional 194,912 shares during the period. Finally, Invesco Ltd. increased its stake in Doximity by 4.2% in the fourth quarter. Invesco Ltd. now owns 2,426,819 shares of the company’s stock valued at $107,460,000 after purchasing an additional 98,519 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Key Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted earnings of $0.26 per share, beating the lower analyst estimate of $0.17, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. Doximity Earnings Report
• Neutral Sentiment: The company’s high margin profile remained intact, with a 23.84% return on equity and 37.54% net margin, suggesting continued operational efficiency. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Despite the earnings beat versus one estimate, Doximity missed the broader Zacks consensus of $0.28 per share, which may have disappointed traders looking for a stronger beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: More importantly for investors, Doximity’s first-quarter FY2027 revenue guidance of $151 million to $152 million came in below the $153.2 million consensus, and full-year FY2027 revenue guidance of $664 million to $676 million also missed the $696 million estimate, signaling a softer outlook. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: The stock also faced added caution from an insider sale earlier in the week, though it was disclosed as part of a pre-arranged 10b5-1 plan and tax withholding related to equity vesting. Insider Trade Disclosure

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.